Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 4/20 | 0.36 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 5/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vindeburnol SCHEMBL9502282 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL2110451 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL29789430 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL29781403 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL2233670 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL14194221 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL15100271 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL12345800 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| Vindeburnol SCHEMBL9501993 | 1.00 | PDE1A (0.36) | PDE1APDE1BPDE1CCYP3A4LMNA | |
| SCHEMBL9318583 | 0.85 | GAA (0.34) | SLC6A4CHRNA7GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0317426-B1 | OPTICALLY ACTIVE PRODUCTS OF DERIVATIVES OF 20,21-DINOREBURNAMENINE, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1993-06-02 | — | — | EP | claimed |
| US-20130178493-A1 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION AND SLEEP/WAKING CYCLE DISORDERS | BIOCORTECH (FR) | 2013-07-11 | — | — | US | disclosed |
| US-20130178493-A1 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION AND SLEEP/WAKING CYCLE DISORDERS | BIOCORTECH (FR) | 2013-07-11 | — | — | US | disclosed |
| EP-1727543-B1 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION | MARCO POLO PHARMACEUTICALS (FR) | 2012-08-15 | — | — | EP | disclosed |
| US-20110201636-A1 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION AND SLEEP/WAKING CYCLE DISORDERS | BIOCORTECH | 2011-08-18 | — | — | US | disclosed |
| US-20110201636-A1 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION AND SLEEP/WAKING CYCLE DISORDERS | BIOCORTECH | 2011-08-18 | — | — | US | disclosed |
| US-7354918-B2 | Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol and applications thereof | BIOCORTECH (FR) | 2008-04-08 | — | — | US | disclosed |
| US-20070155769-A1 | Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders | BIOCORTECH | 2007-07-05 | — | — | US | disclosed |
| US-20070155769-A1 | Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders | BIOCORTECH | 2007-07-05 | — | — | US | disclosed |
| US-20070088046-A1 | Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol, and applications thereof | BIOCORTECH (FR) | 2007-04-19 | — | — | US | disclosed |
| US-5034396-A | Antidepressants | ROUSSEL UCLAF (FR) | 1991-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201636-A1 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION AND SLEEP/WAKING CYCLE DISORDERS | HCRTR1, HCRTR2, COX15 | PDE1A 2862/4885PDE1B 3001/4885PDE1C 3716/4885 |
| US-20130178493-A1 | USE OF 14,15-DIHYDRO-20,21-DINOREBURNAMENIN-14-OL FOR THE TREATMENT AND/OR PREVENTION OF SERIOUS DEPRESSION AND SLEEP/WAKING CYCLE DISORDERS | HCRTR1, HCRTR2, COX15 | PDE1A 2862/4885PDE1B 3001/4885PDE1C 3716/4885 |
| US-20070155769-A1 | Use of 14,15-dihydro-20,21-dinoreburnamenin-14-ol for the treatment and/or prevention of serious depression and sleep/waking cycle disorders | HCRTR1, HCRTR2, COX15 | PDE1A 2862/4885PDE1B 3001/4885PDE1C 3716/4885 |
| US-20070088046-A1 | Derivatives of 14.15-dihydro 20.21-dinoreburnamenin-14-ol, and applications thereof | CYP11B1, CYP11B2, CYP2C18 | PDE1A 2058/4885PDE1B 1995/4885PDE1C 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.